Quick Takeaways
- Invus Global Management, LLC filed SCHEDULE 13G/A for Tango Therapeutics, Inc. Common Stock, $0.001 par value per share (TNGX).
- Disclosed ownership: 6.1%.
- Date of event: 31 Dec 2025.
Invus Global Management, LLC - 31 Dec 2025 SCHEDULE 13G/A Report for Tango Therapeutics, Inc. Common Stock, $0.001 par value per share (TNGX)
- Filing Manager
- Invus Global Management, LLC
- Reporting Manager
- Raymond Debbane
- Symbol
- TNGX
- Shares outstanding
- 133,858,590 shares
- Disclosed Ownership
- 8,165,374 shares
- Ownership
- 6.1%
- Form type
- SCHEDULE 13G/A
- Filing time
- 13 Feb 2026, 11:47:30 UTC
- Date of event
- 31 Dec 2025
- Previous filing
- 22 Sep 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Invus Global Management, LLC disclosed 6.1% ownership in Tango Therapeutics, Inc. Common Stock, $0.001 par value per share (TNGX) on 31 Dec 2025."
What Changed
- Previous schedule filing date: 22 Sep 2025.
- Current filing was accepted on 13 Feb 2026, 11:47.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (8)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Invus Public Equities, L.P. | 5.3% | 7,068,444 | 7,068,444 | 0 | /s/ Raymond Debbane | Raymond Debbane, President of Invus Public Equities Advisors, LLC, its general partner | |
| Invus Public Equities Advisors, LLC | 5.3% | 7,068,444 | 7,068,444 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Invus Global Management, LLC | 5.3% | 7,068,444 | 7,068,444 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Siren, L.L.C. | 5.3% | 7,068,444 | 7,068,444 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Avicenna Life Sci Master Fund LP | 0.8% | 1,096,930 | 1,096,930 | 0 | /s/ Raymond Debbane | Raymond Debbane, Chief Executive Officer of Avicenna Life Sci Master GP LLC, its general partner | |
| Avicenna Life Sci Master GP LLC | 0.8% | 1,096,930 | 1,096,930 | 0 | /s/ Raymond Debbane | Raymond Debbane, Chief Executive Officer | |
| Ulys, L.L.C. | 0.8% | 1,096,930 | 1,096,930 | 0 | /s/ Raymond Debbane | Raymond Debbane, President | |
| Raymond Debbane | 6.1% | 8,165,374 | 8,165,374 | 0 | /s/ Raymond Debbane | Raymond Debbane |